查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968412

癌症生物療法市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、通路、地區和競爭格局分類，2021-2031年

Cancer Biological Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球癌症生物療法市場預計將從 2025 年的 1,161.2 億美元成長到 2031 年的 1,820.3 億美元，複合年成長率達到 7.78%。

癌症生物療法是指利用活體生物、其衍生物或實驗室設計的生物製劑來刺激免疫系統識別並摧毀癌細胞的特殊治療方法。推動這一市場發展的關鍵因素包括全球癌症發病率的上升以及臨床治療向精準醫療的轉變，精準醫療優先採用標靶生物干預而非傳統的特異性療法。美國癌症協會預測，到2024年，美國將新增2,001,140例癌症病例，這意味著需要有效治療方案的患者群體將顯著擴大。

市場概覽
預測期 2027-2031
市場規模：2025年 1161.2億美元
市場規模：2031年 1820.3億美元
複合年成長率：2026-2031年 7.78%
成長最快的細分市場 單株抗體
最大的市場 北美洲

儘管市場需求強勁，但由於研發和生產這些複雜生物製藥的成本極為高昂，市場面臨許多障礙。這些經濟障礙導致治療價格高昂，對醫療預算造成壓力，並限制了病患的就醫機會，尤其是在健保報銷機制有限的發展中地區。

市場促進因素

新型生物製藥的快速法規核准途徑從根本上改變了全球癌症生物治療市場，縮短了從臨床檢驗到患者用藥的時間。監管機構正在擴大快速核准流程的應用範圍，以加速創新治療方法（尤其是針對罕見疾病和難治性癌症的療法）的上市。這種精簡的環境不僅促進了藥物創新，也確保了治療方案的快速擴展。例如，美國癌症研究協會（AACR）在其2024年1月出版的《癌症研究催化劑》（Cancer Research Catalyst）雜誌中指出，美國食品藥物管理局（FDA）在2023年核准了45種抗癌藥物，顯示這些複雜治療方法的上市核准勢頭持續強勁。

同時，靶向單株抗體的日益普及仍然是市場收入和臨床實踐的主要驅動力。這些生物製藥已成為多種固態腫瘤的標準治療方案，憑藉其在一線治療和輔助性治療中的高使用率，推動了顯著的商業性成長。關鍵查核點抑制劑的優異表現反映了該領域的經濟規模。根據默克公司於2024年2月發布的《2023年第四季及全年財務業績報告》，Keytruda的年銷售額在2023年成長了19%，達到250億美元。這項商業性成功得益於公司在創新方面的大量資本投入。根據百時美施貴寶公司於2024年3月發布的《2023會計年度年度報告》，該公司宣布投資93億美元用於研發，以推動其產品系列的發展。

市場挑戰

複雜生物製藥的研發和生產高成本，是全球癌症生物療法市場成長的主要障礙。不斷飆升的生產成本迫使製藥公司採取高價策略以收回研發投資，最終加重了全球醫療預算和保險體系的負擔。因此，已開發國家和開發中國家的支付方都在實施更嚴格的報銷標準，並擴大延遲或拒絕支付這些先進療法的費用。這種財務摩擦限制了能夠接受治療的患者群體，並阻礙了臨床有效治療方法的市場滲透。

根據美國癌症協會預測，到2025年，許多新型抗癌藥物的年度定價將超過10萬美元，給病患和醫療系統帶來沉重的經濟負擔。這種定價結構導致患者因經濟壓力過大而放棄治療的比例居高不下，直接阻礙了市場成長。臨床需求與經濟可行性之間的差距降低了生物療法的商業性應用，也阻礙了市場充分發揮其獲利潛力。

市場趨勢

癌症生物相似藥的迅速普及，透過提供價格低廉的替代療法，從根本上改變了市場結構，取代了價格昂貴的原廠生物製藥。這一趨勢的主要促進因素是重磅藥物專利到期，以及在不影響臨床療效的前提下最佳化醫療成本的迫切需求。生物相似藥以更低的價格提供臨床療效相當的治療方案，擴大了患者獲得必要生物療法的機會，尤其是在資源匱乏的環境中。這種經濟轉變至關重要。根據美國可及藥品協會（Association for Accessible Medicines）於2025年9月發布的《2025年美國非專利和生物類似藥節省報告》，自生物類似藥上市以來，該行業已累計為患者和醫療系統節省了562億美元。

同時，抗體藥物複合體（ADC）的研發正蓬勃發展，為標靶癌症治療樹立了新的典範。製藥公司正大力投資於這項療法，該療法結合了單株抗體的特異性和細胞毒性藥物的療效，能夠將藥物直接遞送至癌細胞，同時最大限度地減少目標外毒性。這種趨勢推動了已通過核准的ADC的快速商業性成長，展現了其在多種適應症中取代傳統化療的潛力。根據輝瑞公司於2025年8月發布的2025年第二季財報，其抗體藥物複合體Padsev的全球銷售額達到5.42億美元，年增38%，反映了市場對這種精準藥物的高臨床需求和市場滲透率。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球癌症生物療法市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（癌症生長抑制劑、單株抗體、疫苗）
    • 通路（醫院、零售/郵購藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美癌症生物療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲癌症生物療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區癌症生物療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲癌症生物療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲癌症生物療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球癌症生物療法市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck KgAa
  • Amgen Inc
  • GSK PLC
  • Celgene Corp
  • Pfizer Inc
  • Zydus Lifesciences Ltd
  • Sun Pharmaceutical Industries Ltd
  • Bayer AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18861

The Global Cancer Biological Therapy Market is projected to expand from USD 116.12 Billion in 2025 to USD 182.03 Billion by 2031, achieving a compound annual growth rate of 7.78%. Cancer biological therapy refers to a specialized class of treatments that utilize living organisms, their derivatives, or laboratory-engineered versions to prompt the immune system to identify and destroy malignant cells. The primary forces driving this market include the rising global incidence of cancer and a clinical shift toward precision medicine, which prioritizes targeted biological interventions over traditional non-specific treatments. As reported by the American Cancer Society, the United States was expected to see 2,001,140 new cancer cases in 2024, highlighting the substantial and expanding patient population in need of effective therapeutic options.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 116.12 Billion
Market Size 2031USD 182.03 Billion
CAGR 2026-20317.78%
Fastest Growing SegmentMonoclonal Antibodies
Largest MarketNorth America

Despite robust demand, the market faces significant hurdles due to the prohibitive costs associated with developing and manufacturing these complex biologics. This financial barrier leads to high treatment prices that strain healthcare budgets and restrict patient access, particularly in developing regions with limited reimbursement frameworks.

Market Driver

Accelerated regulatory pathways for new biologics have fundamentally transformed the Global Cancer Biological Therapy Market by shortening the timeline between clinical validation and patient availability. Regulatory agencies have increasingly adopted expedited review processes to speed up the entry of innovative therapies, particularly for rare and refractory cancers. This streamlined environment not only encourages pharmaceutical innovation but also ensures the rapid broadening of treatment options. For instance, the American Association for Cancer Research noted in its January 2024 'Cancer Research Catalyst' that the U.S. Food and Drug Administration approved 45 oncology drugs in 2023, demonstrating the continued momentum of market authorizations for these complex interventions.

Concurrently, the growing adoption of targeted monoclonal antibodies remains a primary driver of market revenue and clinical practice. These biologic agents have become the standard of care for numerous solid tumors, driving significant commercial growth through high utilization in both first-line and adjuvant settings. The financial scale of this segment is illustrated by the performance of leading checkpoint inhibitors; according to Merck & Co.'s 'Fourth-Quarter and Full-Year 2023 Financial Results' released in February 2024, annual sales of Keytruda rose 19% to $25.0 billion in 2023. This commercial success is supported by massive capital investment in innovation, as evidenced by Bristol Myers Squibb's '2023 Annual Report' from March 2024, which reported a $9.3 billion investment in research and development to advance its portfolio.

Market Challenge

The high costs associated with the development and manufacturing of complex biologics represent a major obstacle to the growth of the Global Cancer Biological Therapy Market. These elevated production expenses force pharmaceutical companies to adopt premium pricing strategies to recoup their research and development investments, thereby straining healthcare budgets and insurance systems worldwide. Consequently, payers in both developed and developing regions are enforcing stricter reimbursement criteria, often delaying or denying coverage for these advanced treatments. This financial friction limits the accessible patient population and impedes the market penetration of otherwise clinically effective therapies.

According to the American Cancer Society, in 2025, the annual list price for many new cancer prescription medicines exceeded $100,000, creating a severe financial burden for patients and healthcare systems. This pricing structure directly hampers market growth by fueling high rates of financial toxicity, which frequently compels patients to forgo or discontinue necessary treatment. The resulting gap between clinical necessity and economic feasibility reduces the commercial adoption of biological therapies, preventing the market from realizing its full revenue potential.

Market Trends

The rapid adoption of oncology biosimilars is fundamentally restructuring the market by introducing cost-effective alternatives to expensive reference biologics. This trend is primarily driven by the patent expiration of major blockbuster drugs and the intensified need for healthcare systems to optimize spending without compromising clinical outcomes. By offering clinically equivalent therapeutic options at reduced prices, biosimilars are expanding patient access to essential biological treatments, particularly in resource-constrained settings. This economic shift is significant; according to the Association for Accessible Medicines' '2025 U.S. Generic & Biosimilar Medicines Savings Report' from September 2025, the biosimilars industry has generated $56.2 billion in cumulative savings for patients and the healthcare system since these agents first entered the market.

At the same time, a surge in the development of antibody-drug conjugates (ADCs) is establishing a new paradigm in targeted cancer intervention. Pharmaceutical companies are heavily investing in this modality, which combines the specificity of monoclonal antibodies with the potency of cytotoxic agents to deliver payloads directly to tumor cells while minimizing off-target toxicity. This focus has translated into rapid commercial growth for approved ADCs, validating their potential to replace conventional chemotherapy in multiple indications. According to Pfizer Inc.'s 'Second-Quarter 2025 Earnings' report from August 2025, global sales of the antibody-drug conjugate Padcev increased 38% year-over-year to reach $542 million, underscoring the high clinical demand and market uptake for these precision therapeutics.

Key Market Players

  • F Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck KgAa
  • Amgen Inc
  • GSK PLC
  • Celgene Corp
  • Pfizer Inc
  • Zydus Lifesciences Ltd
  • Sun Pharmaceutical Industries Ltd
  • Bayer AG

Report Scope

In this report, the Global Cancer Biological Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Biological Therapy Market, By Product

  • Cancer Growth Blockers
  • Monoclonal Antibodies
  • Vaccines

Cancer Biological Therapy Market, By Distribution Channel

  • Hospitals
  • Retail & Mail Order Pharmacies

Cancer Biological Therapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Biological Therapy Market.

Available Customizations:

Global Cancer Biological Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Biological Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines)
    • 5.2.2. By Distribution Channel (Hospitals, Retail & Mail Order Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cancer Biological Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cancer Biological Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Cancer Biological Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Cancer Biological Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Distribution Channel

7. Europe Cancer Biological Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cancer Biological Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Cancer Biological Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Cancer Biological Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Cancer Biological Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Cancer Biological Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Cancer Biological Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cancer Biological Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Cancer Biological Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Cancer Biological Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Cancer Biological Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Cancer Biological Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Cancer Biological Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cancer Biological Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Cancer Biological Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Cancer Biological Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Distribution Channel

10. South America Cancer Biological Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Biological Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Cancer Biological Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Cancer Biological Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cancer Biological Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F Hoffmann-La Roche Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Merck KgAa
  • 15.4. Amgen Inc
  • 15.5. GSK PLC
  • 15.6. Celgene Corp
  • 15.7. Pfizer Inc
  • 15.8. Zydus Lifesciences Ltd
  • 15.9. Sun Pharmaceutical Industries Ltd
  • 15.10. Bayer AG

16. Strategic Recommendations

17. About Us & Disclaimer